Talk: Landscape of mutational processes and driver mutations in human cancers.

Abstract: Cancer is caused by genetic mutations, often referred to as “drivers”, that confer selective growth advantage to malignant cells. However, the identification of driver mutations in sequenced cancer genomes is challenging and requires a detailed understanding of the underlying mutational processes (i.e., how somatic mutations are accumulated and distributed in the genome of cancer cells during their development), especially in functionally crucial regions such as in genes and regulatory regions. In this talk, I will present our recent findings on how DNA-binding regulatory proteins (like transcription factors), and the chromatin structure of exons and introns in genic regions influence the local somatic mutation rate in the cancer genomes [1, 2]. These findings have important implications for the understanding of mutational and DNA repair processes, as well as for the identification of cancer driver mutations. Furthermore, in the last part of the talk, I will present our current work on the analysis of whole genomes of 2,500 tumors from 37 types of cancer to identify the landscape of coding and non-coding driver mutations in each patient’s tumor. This study reveals that genomic events are at the root of virtually all tumors (with each carrying on average 4.6 driver mutations), and importantly most individual tumors harbor a unique combination of driver mutations.

Biosketch: Sabarinathan Radhakrishnan is a post-doctoral researcher in the group of Prof. Nuria Lopez-Bigas at the Institute for Research in Biomedicine (IRB), Barcelona, Spain. He obtained his PhD from the University of Copenhagen (Denmark) in 2014. Prior to that, he studied Bioinformatics and then worked as a research assistant at the Indian Institute of Science, Bangalore, India.

References:

Venue: Auditorium F, Building 1534, room 125, Ny Munkegade, 8000 Aarhus C.

Refreshments: Sandwiches will be served after the talk. Therefore, please email Anne Hedemand (anne@biomed.au.dk) no later than 22 May 2018, if you would like to participate.